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Hepatoma cella b s t r a c t
Although microRNA-1 (miR-1) is a known liver cancer suppressor, the role of miR-1 in apoptosis of
hepatoma cells has remained largely unknown. Our study shows that ectopic miR-1 overexpression
induced apoptosis of liver hepatocellular carcinoma (HepG2) cells. Apoptosis inhibitor 5 (API-5) was
found to be a potential regulator of miR-1 induced apoptosis, using a bioinformatics approach.
Furthermore, an inverse relationship between miR-1 and API-5 expression was observed in human
liver cancer tissues and adjacent normal liver tissues. Negative regulation of API-5 expression by
miR-1was demonstrated to promote apoptosis of HepG2 cells. Our study provides a novel regulatory
mechanism of miR-1 in the apoptosis of hepatoma cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction recurrence, and metastasis of HCC as well as its resistance to che-Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer and the third leading cause of cancer death worldwide
[1]. Although the mechanism of cytological pathogenesis of HCC
remains unclear, emerging evidence has revealed that microRNAs
(miRNAs) play important roles in the initiation, progression,motherapy and radiotherapy [2–4]. microRNA-1 (miR-1) has been
demonstrated to be a tumor-suppressive miRNA in various cancers
including lung cancer, colorectal cancer, prostate cancer, thyroid
carcinoma, rhabdomyosarcoma, and head and neck squamous cell
carcinoma [5–11]. Some oncogenes, such as MET proto-oncogene
(MET), histone deacetylase 4 (HDAC4), forkhead box P1 (FOXP1),
G1/S-speciﬁc cyclin-D2 (CCND2), C-X-C chemokine receptor type
4 (CXCR4) and stromal cell-derived factor 1 (SDF-1), have been con-
ﬁrmed to be targets of miR-1 that mediate its tumor-suppressive
effects [5,8,12]. Recently, it was reported that methylation-
mediated silencing of themiR-1 gene signiﬁcantly induced the pro-
liferation of hepatoma cells, whereas ectopicmiR-1 overexpression
in these cells inhibited cell proliferation, migration and invasion,
indicating that miR-1 also exhibits tumor suppressor functionality
in HCC [13,14]. In addition, our previous study further indicated
that miR-1 inhibited the proliferation of hepatoma cells by target-
ing a potent mitogen: endothelin-1 (ET-1) [15,16]. Disruption of
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cause of carcinogenesis, and reduced apoptosis leads to the occur-
rence of HCC and tumor growth. It has been reported that miR-1
can activate apoptosis by targeting prothymosin alpha in nasopha-
ryngeal carcinoma cells [17]. The promotion of apoptosis was also
observed following miR-1 transfection into bladder cancer and
malignant mesothelioma cells [18,19]. In HCC, Datta et al. found
that ectopic expression of miR-1 induced HepG2 cell apoptosis
in vitro [13]. However, the mechanisms underlying this phenome-
non are still largely unknown.
In accordance with previous research, we observed that ectopic
miR-1 overexpression induced the apoptosis of hepatoma cells in
this study. Moreover, we found that miR-1 suppressed the malig-
nant properties of HCC not only in vitro but also in vivo. Bioinfor-
matics was used to elucidate the mechanism underlying these
processes, and the anti-apoptotic factor apoptosis inhibitor-5
(API-5) was found to be a potential target of miR-1 and an impor-
tant player in miR-1-induced apoptosis. Up-regulation of API-5
and down-regulation ofmiR-1were detected in human liver cancer
samples compared with adjacent non-tumor liver tissues. Negative
regulation of API-5mRNA and protein levels by miR-1 in hepatoma
cells was further demonstrated, and dual-luciferase reporter assays
conﬁrmed thatmiR-1 directly bound to the 30UTR of API-5mRNA to
silence API-5 expression. Furthermore, ectopic rescue of API-5 par-
tially reversed the effect of miR-1 on HepG2 cells, indicating that
miR-1 promoted apoptosis of HepG2 cells by directly targeting
API-5. Due to the down-regulation of miR-1 and up-regulation of
API-5 in human liver cancer tissues, our ﬁndings imply that miR-
1 plays a role in apoptosis mediated by API-5 in liver cancer cells,
reafﬁrming the important role of miR-1 in the dysregulation of
cellular apoptosis that may ultimately lead to tumorigenesis.
2. Materials and methods
2.1. Cell culture and clinical HCC specimen collection
The human HCC cell lines HepG2 and Hep3B were obtained
from the American Type Culture Collection (ATCC), and the Huh7
cell line was obtained from the Cell Bank of the Chinese Academy
of Sciences (Shanghai, China). Genotype validation of the cell lines
was performed once a year to ensure that the genotypes remained
stable. The HepG2 and Hep3B cells were maintained in Eagle’s
minimum essential medium (MEM) (Gibco, Rockville, MD, USA)
with 10% fetal bovine serum, penicillin (50 units/ml) and strepto-
mycin (50 lg/ml) at 37 C with 5% CO2. The Huh7 cells were incu-
bated under the same conditions but cultured in Dulbecco’s
minimal essential medium (DMEM) (Gibco, Rockville, MD, USA)
containing 10% fetal bovine serum, penicillin (50 unit/ml) and
streptomycin (50 lg/ml). Primary tumor and adjacent non-tumor
tissues were obtained from 24 HCC patients during surgery at
the Chengdu Military General Hospital (Chengdu, China) prior to
any therapeutic intervention, such as chemotherapy, radiotherapy
or interposition embolism. All the samples were subsequently ver-
iﬁed by histology. Informed consent was obtained from all
patients, and the study protocol was approved by the Clinical
Research Ethics Committee of Chengdu Military General Hospital
(Chengdu, China). The specimens were stored at 80 C until
RNA and whole-cell extracts were collected for real-time PCR and
western blot analysis, respectively.
2.2. Plasmid construction and RNA synthesis
The miRNA expression vector pSuper was obtained from Oli-
goEngine. Sub-cloning of hsa-pre-miR-1 fragment into pSuper to
form the expression vector pSuper-miR-1 has been described in
previous studies [15,16].The luciferase reporter vector pGL3 (Promega, Madison, WI,
USA) was used to generate the luciferase constructs. A 2035-nt
region of the wild-type 30-UTR of the API-5 gene was ampliﬁed
using the following primers: 50-TATATCTAGAGGTT GGGGCACAC-
GAGGAAA-30 (forward) and 50-TATATCTAGAGCATAAGGGGA CAT-
TTACATTTAA-30 (reverse). Then, the PCR products were digested
with XbaI, and the fragment was cloned downstream of the open
reading frame (ORF) of the luciferase reporter gene. The mutant
pGL3-API-5-30UTR was generated by PCR mutagenesis using the
following primers: 50-AGTGGTGGCAATAATCTCTAAAGA TTAGAAAA
GACCATGAGCTGAACCTA-30 (forward) and 50-TAGGTTCAGCTC
ATGGTCTTTTCTAATCTTTAGAGATTATTGCCACCACT-30 (reverse).
The eukaryotic expression plasmid pEX-1 (GenePharma, Shang-
hai, China) was used to construct an API-5 expression plasmid. A
fragment of the API-5 gene coding sequence was ampliﬁed from
cDNA obtained from HepG2 cells using the following primers:
50-GATATGGCTAGCGCCACCATGCCGACAGT-30 (forward) and 50-CT
CTAGGAATTCTCAGTAGAGTCTTCCCCGACTACGATTTCCTC-30 (reverse).
Then, the PCR product was inserted between the NheI and EcoRI
sites in the multiple cloning site (MCS) of pEX-1.
20-O-methyl-modiﬁed antisense RNA oligonucleotides for
miR-1 were synthesized by Ambion (Ambion, Austin, Texas, USA)
and transfected into hepatoma cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). The sequence of the oligonucleotide
was 50-AUACAUACUUCUUUACAUUCCA-30. Scrambled oligonucleotide
was used as a negative control, and its sequence was 50-CAGUACUU
UUGUGUAGUACAA-30.
2.3. RNA extraction, real-time PCR and RT-PCR
Total RNA was extracted using Trizol reagent according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). Real-
time PCR for miR-1 detection was performed as previously
described [15,16]. Real-time PCR and semi-quantitative reverse
transcription PCR (RT-PCR) for API-5 mRNA detection were per-
formed using the same strategy. For semi-quantitative RT-PCR,
the PCR reaction was terminated at 15 cycles, and the products
were electrophoresed on a 2% agarose gel. The primers used for
API-5 detection were as follows: 50-TAGTGGGTTTGGAGAA GTTC-
30 (forward) and 50-TCACTTGATAGGCATCTTTATG-30 (reverse). The
mRNA levels were normalized to the housekeeping gene b-actin
using the following primers: 50-GTGGCATCCACGAAACTACC-30
(forward) and 50-AGGGCAGTGAT CTCCT TCTG-30 (reverse).
2.4. Western blot analysis
Proteins were extracted from total cell lysates using sodium
dodecyl sulfate (SDS) buffer. The proteins were resolved by
SDS-PAGE using a 12% polyacrylamide gel and transferred onto
polyvinylidene ﬂuoride membranes. The membranes were probed
with monoclonal antibodies against API-5 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and b-actin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). SuperSignal chemiluminescence reagent (Pierce,
Rockford, IL, USA) was used to detect API-5 protein. Quantitative
analysis was performed using Quantity One software (Bio-Rad,
Hercules, CA, USA).
2.5. Bioinformatics analysis and luciferase assay
A search for potentialmiR-1 targets was performed using the fol-
lowing websites for miRNA bioinformatics analysis: TargetScan
(http://www.targetscan.org/) Pictar (http://pictar.mdc-berlin.de/)
and BiBiserve (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/).
For luciferase assays, HEK 293 cells were plated in 24-well plates
and grown to 80–90%conﬂuency. The cellswere co-transfectedwith
different amounts of the miR-1 expression vector pSuper-miR-1
Fig. 1. miR-1 suppressed the malignant properties of HCC in vitro and in vivo. (A) MTT assay to evaluate HepG2 cell proliferation at 0, 24, 48, 72 and 96 h after pSuper-miR-1
(denoted as miR-1) or pSuper (denoted as NC) transfection. The growth curve of miR-1-transfected cells is represented by black squares, and NC-transfected cells are
represented by white triangles. (B) Scratch wound assay to examine cell motility of HepG2 cells transfected with miR-1 and NC for 48 h. (C) Annexin V analysis of apoptotic
cells after miR-1 and NC transfection. The lower right quadrant of the ﬂow cytometry ﬁgure represents early apoptotic cells. The percentage of early apoptotic HepG2 cells is
shown in the histogram on the right. (D) Clonogenic survival assay of HepG2 cells transfected with miR-1 and NC. (E) Tumorigenicity in vivo. The growth of subcutaneous
tumors in BALB/c nude mice implanted withmiR-1-overexpressing HepG2 cells or NC HepG2 cells after 6 weeks is shown on the left, and the volume and relative weight ratio
(tumor weight/total mouse weight) of excised tumors are shown on the right. Data from at least three independent experiments are shown. ‘‘⁄’’ Represents P < 0.05; ‘‘⁄⁄’’
represents P < 0.01.
70 D. Li et al. / FEBS Letters 589 (2015) 68–76(0.5 lg, 1.0 lg and 2.0 lg) or equivalent amounts of the control
vector pSuper, 100 ng of a luciferase reporter vector containing
the wild-type API-5 30UTR (pGL3-API-5-30UTR-WT) or mutant
API-5 30UTR (pGL3-API-5-30UTR-Mut), and 10 ng of the control
renilla luciferase vector pRL-TK (Promega, Madison, Wisconsin,
USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Luciferase activity was measured with a dual luciferase assay kit
(Promega, Madison, Wisconsin, USA) using the M200 microplate
ﬂuorescence reader (TecanSaﬁre, Männedorf, Switzerland) 48 h
after transfection according to the manufacturer’s instructions.
The pRL-TK vector, which constitutively expresses renilla luciferase,
was used as an internal control to correct for differences in both
transfection and harvest efﬁciencies. The transfections wereperformed in duplicate and repeated at least three times in indepen-
dent experiments.
2.6. Cell proliferation assay
HepG2 cells were plated in 96-well plates at 4  103 cells/well
and grown to 80–90% conﬂuency before transfection. A total of
150 ng of pSuper-miR-1 or pSuper was used to transfect the cells
in each well. At 24 h after transfection, cell proliferation was
assessed using the CellTiter 96 AQueous One Solution Cell Prolif-
eration Assay (MTS) (Promega, Madison, WI, USA) according to the
manufacturer’s instructions; subsequently, cell proliferation was
documented every 24 h for 4 days. Proliferation was assessed by
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reader (Molecular Devices, Sunnyvale, CA, USA).
2.7. Cell motility assay
HepG2 cells were plated in 6-well plates and grown to 80–90%
conﬂuency before being transfected with 4 lg of pSuper-miR-1 or
pSuper and placed in serum-free medium for 24 h. Wounds were
generated in conﬂuent HepG2 cells using a pipette tip, and the cells
were rinsed with phosphate-buffered saline prior to the addition of
fresh culture medium. Wounded areas were marked and photo-
graphed at 0 and 48 h using a phase-contrast microscope.
2.8. Colony-forming assay
HepG2 cells seeded in 6-well plates were transfected with 4 lg
of pSuper-miR-1 or pSuper using Lipofectamine 2000. At 48 h post-
transfection, the cells were collected and seeded (3  103/well) in
6-well plates for 14 days. Colonies were then ﬁxed with 70% etha-
nol, stained with crystal violet solution, and counted.
2.9. FACS assay for apoptosis
HepG2 cells seeded in 24-well plates were transfected with
either 2 lg of pSuper-miR-1 or pSuper using Lipofectamine 2000.
For the API-5 rescue assay, HepG2 cells were co-transfected withFig. 2. Apoptosis inhibitor-5 (API-5) is a putative target of miR-1. (A) Base-pairing
of miR-1 and its predicted binding site within the 30UTR of API-5 mRNA. An eight-
nucleotide ‘‘seed sequence’’, which is the main determining factor for the
interaction between the miRNA and its target gene, was located between
nucleotides 1550 and 1557 of the API-5 30UTR. (B) Secondary structure of the
target site duplex consisting of the API-5 30UTR and miR-1 with the free energy of
hybrids (Mef). (C) The 8-bp ‘‘seed sequence’’ for miR-1 in the 30UTR of API-5 is
conserved across species; mRNA pairing is outlined in red, and nucleotides that
differ across species are highlighted in blue. Hsa: human, Ptr: chimpanzee, Mmu:
mouse, Rno: rat, Cpo: guinea pig, Cfa: dog, Fca: cat, Eca: horse, Bta: cow.2 lg of pSuper-miR-1 and 2 lg of the API-5-expressing vector
pEX-1-API-5. All the cells were collected 48 h after transfection,
and apoptosis was assessed with the annexin V-APC apoptosis
detection kit with propidium iodide (PI) (Biolegend, San Diego,
CA, USA) following the manufacturer’s protocol. All cells were
washed twice with cell staining buffer and suspended in binding
buffer at a density of 3  106 cells/ml, and 5 ll of annexin V-APC
and 10 ll of PI solution were added successively to the cell suspen-
sion. Then, the reaction was mixed gently and incubated in the
dark at 25 C for 15 min. Subsequently, ﬂow cytometry was per-
formed to examine the percentage of apoptotic cells. The early
apoptotic cells were labeled with high annexin V-APC ﬂuorescence
and low PI ﬂuorescence.
2.10. Animals and in vivo xenograft tumorigenicity assay
Athymic nude mice (BALB/C-nu/nu, 4–6 weeks old, male) were
obtained from the Animal Center of Sichuan University (Chengdu,
China), housed under speciﬁc pathogen-free conditions and cared
for in accordance with the guidelines of the laboratory animal cen-
ter of Chengdu Medical College (Chengdu, China). All studies
involving animals were approved by the Research Animal Care
and Use Committee of Chengdu Medical College.Fig. 3. Analysis of API-5 protein and miR-1 expression in human primary liver
cancer and matching healthy liver tissues. (A) Western blot analysis of API-5
protein expression in 24 clinical primary liver cancer tissue samples and adjacent
paired non-cancerous liver tissue samples. (B) Quantiﬁcation and statistical analysis
of Western blots was performed using Quantity One software (Bio-Rad). (C) Real-
time PCR analysis of miR-1 levels in the 24 human primary liver cancer tissue
samples and matching liver tissue samples. T denotes tumor tissue from HCC
patients, whereas N represents the paired non-tumorous liver tissues. Data from at
least three independent experiments are shown. ‘‘⁄’’ Represents P < 0.05.
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hsa-pre-miR-1 fragment was cloned into the pWPXLd plasmid
(Addgene, Cambridge, MA, USA) between the EcoRI and SpeI sites
located downstream of the ORF of the EGFP gene. The pWPXLd-
miR-1 plasmid was co-transfected into 293FT cells with the
lentiviral packaging plasmids psPAX2 and pLP/VSVG (Invitrogen,
Carlsbad, CA, USA), and 48 h later, the lentivirus in the media
was collected, ﬁltered, and used to infect HepG2 cells. For the
establishment of stable miR-1-overexpressing and control cell
lines, HepG2 cells were infected with either the miR-1-expressing
lentivirus (Lenti-miR-1) or the control lentivirus (Lenti-NC). Next,
ﬂow cytometry sorting was performed to isolate the infected cells
(GFP-positive). The cells were maintained in culture medium for
5–7 days before undergoing GFP selection again, and stable clones
were obtained after 2 rounds of GFP selection. Overexpression of
miR-1 in the stable cell lines was conﬁrmed by real-time PCR.
BALB/c nude mice were assigned to 2 groups of 6 mice each. Either
HepG2 cells stably overexpressing miR-1 or control HepG2 cells
were implanted into the left ﬂanks of the mice at a density of
1.0  106 cells/100 ll in H-DMEM without FBS. The tumor-bearing
mice were sacriﬁced 6 weeks after inoculation, and the tumors
were excised and weighed. Tumor volume was calculated usingFig. 4. Ectopic expression of miR-1 suppressed API-5 mRNA and protein expression in h
with miR-1 (denoted as miR-1) and control vector (denoted as NC). (B) Real-time PCR (lef
HepG2 cells transfected with miR-1 or NC. (C) Western blot analysis of API-5 protein lev
protein levels in HepG2 cells transfected with miR-1 antisense oligonucleotide (AS-miR-1
normalization. Data from at least three independent experiments are shown. ‘‘⁄’’ Represthe formula L  S2/2, where L is the longest tumor diameter and
S is the shortest tumor diameter. The weight of tumor was normal-
ized to the total weight of the mouse.
2.11. Statistical analysis
Quantitative data were expressed as the mean ± S.D. Differences
between groups were determined using a one-way ANOVA
followed by a Student–Newman–Keuls test. A P value <0.05 was
considered to denote statistical signiﬁcance.
3. Results
3.1. miR-1 suppressed the malignant properties of HCC in vitro and
in vivo
To address the anti-tumorigenic function ofmiR-1 in liver cancer
cells, the effects of miR-1 on the malignant properties of HCC
in vitro were examined. We transiently transfected HepG2 cells
with pSuper-miR-1 to overexpress maturemiR-1. Control cells were
transfected with a comparable amount of empty vector. Proliferation
assays revealed that the cell growth of miR-1-overexpressingepatoma cells. (A) Real-time PCR analysis of miR-1 levels in HepG2 cells transfected
t panel) and semi-quantitative RT-PCR (right panel) analysis of API-5 mRNA levels in
els in HepG2 cells transfected with miR-1 or NC. (D) Western blot analysis of API-5
) or scrambled oligonucleotide (AS-NC). The housekeeping gene b-actin was used for
ents P < 0.05; ‘‘⁄⁄’’ Represents P < 0.01.
Fig. 5. Luciferase reporter and mutation assay. (A) Schematic representation of the
predicted sequence of themiR-1 binding site in the 30UTR of API-5 (upper panel). The
nucleotides in red are nucleotides that have been mutated to abolish miR-1 binding
to the API-5 30UTR (lower panel). (B) Luciferase assay to assess the effect ofmiR-1 on
the expression of a pGL3 luciferase reporter construct carrying the wild-type or
mutant 30UTR of API-5. Wild-type (pGL3-API-5-30UTR-WT) or mutant (pGL3-API-5-
30UTR-Mut) reporter constructs were co-transfected with pSuper-miR-1 (miR-1) or
pSuper (NC) as shown. Data from at least three independent experiments are
shown. ‘‘⁄’’ Represents P < 0.05; ‘‘⁄⁄’’ represents P < 0.01.
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reduced by 21% after 48 h (1.134 ± 0.078 vs. 1.436 ± 0.135, P < 0.01)
and 17% after 72 h (1.348 ± 0.093 vs. 1.627 ± 0.143, P < 0.05) relative
to the control cell growth (Fig. 1A). Flow cytometry assays revealed
that miR-1 transfection signiﬁcantly increased the percentage of
apoptotic HepG2 cells (20.80 ± 3.60% vs. 1.93 ± 0.35%, P < 0.01)
compared with the control group (Fig. 1C). A scratch wound assay
was performed to test cell motility and revealed that control HepG2
cells nearly closed the wound within 48 h, whilemiR-1-transfected
cells did not (Fig. 1B). In colony-forming assays, we found that the
clonogenic survival of HepG2 cells was reduced by nearly 60% upon
ectopic expression of miR-1 (79 ± 16.7 vs. 188.67 ± 12.5, P < 0.01)
(Fig. 1D).
To validate the tumor-suppressive effect of miR-1 on HCC
in vivo, a HepG2 cell line stably overexpressing miR-1 was estab-
lished by miR-1 lentivirus infection of HepG2 cells followed by
GFP selection (Supplementary Fig. 1A). miR-1 overexpression in
this stable cell line was conﬁrmed by real-time PCR (Supplemen-
tary Fig. 1B). Stable HepG2 cell lines infected with lentivirus
expressing miR-1 (Lenti-miR-1) or control lentivirus (Lenti-NC)
were subcutaneously injected into the left ﬂanks of BALB/c nude
mice. We observed that xenograft tumors were signiﬁcantly smal-
ler in the lenti-miR-1 group compared with the control group at
6 weeks post-implantation (Fig. 1E, left). Additionally, Lenti-miR-
1-infected HepG2 tumors had a signiﬁcantly reduced volume
(47.32 ± 6.64 vs. 172.66 ± 21.03, P < 0.01) and weight (7.31 ± 1.33
vs. 24.89 ± 4.23, P < 0.01) compared with Lenti-NC-infected tumors
(Fig. 1E, middle and right), indicating that miR-1 markedly dimin-
ished HCC tumorigenicity and displayed a signiﬁcant antitumor
effect in vivo.
3.2. API-5 is a potential target gene of miR-1
To investigate the underlying mechanism of apoptosis induc-
tion by miR-1 in HCC, TargetScan and Pictar software programs
were used to identify putative miR-1 targets with anti-apoptotic
properties. Among these predicted targets, we were particularly
interested in the anti-apoptotic factor API-5. There was only one
putative miR-1 binding site in the API-5 30UTR, which was identi-
ﬁed by the TargetScan and Pictar algorithms. The putative base-
pairing and secondary structure of miR-1 bound to the target site
in the API-5 30UTR are shown in Fig. 2A and B. ThismiR-1 target site
was located between nucleotides 1535 and 1557 of the API-5
30UTR. An eight-nucleotide sequence (nucleotides 1550–1557) in
the binding site was designated as the ‘‘seed sequence’’, and its
continuous complementarity tomiR-1was recognized to be crucial
for their interaction. The free energy of the hybrid (Mef) was
18.5 kcal/mol. The sequence of the ‘‘seed sequence’’ was highly
conserved across species, indicating the importance of miRNA reg-
ulation during evolution (Fig. 2C).
3.3. miR-1 and API-5 expression is inversely correlated in human
primary HCC tissues
We further analyzed the abundance of API-5 protein in 24
human primary HCC tissue samples and paired adjacent normal
tissue samples. Western blot assays showed signiﬁcant up-regula-
tion of API-5 in 19 HCC samples compared with the paired adjacent
normal liver tissue samples (Fig. 3A). Statistical analysis conﬁrmed
an approximate 3-fold up-regulation of API-5 protein levels in HCC
samples compared with matching normal liver tissue samples
(Fig. 3B). In contrast, miR-1 expression, as detected by real-time
PCR, was signiﬁcantly reduced (>50%) in liver tumors relative to
their matched controls (Fig. 3C). These results indicated that the
abundance of API-5 protein and level of miR-1 were inversely
related in both HCC tissues and normal liver tissues.3.4. miR-1 negatively regulated both the mRNA and protein expression
of API-5 in hepatoma cells
To conﬁrm that API-5 is indeed a target ofmiR-1 in HCC cells, we
examined endogenous API-5 expression in hepatoma cells express-
ing ectopic miR-1. Real-time PCR analysis showed that the miR-1
level was increased over 300-fold in HepG2 cells after miR-1 trans-
fection compared with control cells (Fig. 4A). As a result, the mRNA
level of API-5 was dramatically reduced by approximately 7-fold in
miR-1-overexpressing HepG2 cells compared with control cells.
(Fig. 4B, left). Semi-quantitative RT-PCR was used to visualize alter-
ations in the API-5 mRNA level after miR-1 transfection (Fig. 4B,
right). Furthermore, western blot analysis also revealed that API-
5 protein was reduced in a dose-dependent manner with increas-
ing expression of ectopic miR-1 (Fig. 4C). Similarly, reductions in
the levels of API-5 protein and mRNA aftermiR-1 transfection were
observed in two additional hepatoma cell lines: Hep3B and Huh7
(Supplementary Fig. 2A and B). In addition, miR-1-overexpressing
HepG2 cells that were infected with Lenti-miR-1 also exhibited
lower API-5 protein expression compared with control cells that
were infected with Lenti-NC. (Supplementary Fig. 1C). On the other
hand, when themiR-1 expression was down-regulated by transfec-
tion of HepG2 cells with 40 nM or 80 nM antisense miR-1 oligonu-
cleotide (As-miR-1), the level of API-5 protein was increased by
74 D. Li et al. / FEBS Letters 589 (2015) 68–76approximately 50% compared with that in the control cells trans-
fected with the scrambled oligonucleotide (Fig. 4D). Induction of
API-5 protein expression by miR-1 knockdown was also observed
in Hep3B and Huh7 cell lines (Supplementary Fig. 2C). These
results demonstrated that miR-1 could negatively regulate the
expression of API-5 mRNA and protein in hepatoma cells.
3.5. The predicted miR-1 binding site in the API-5 30UTR mediated API-
5 down- regulation
To further investigate the mechanism by which miR-1 regulates
API-5 expression, a region (1–2192) of the wild-type API-5 30UTR
containing the putative miR-1 binding site (1535–1557) was
cloned into the ﬁreﬂy luciferase reporter vector pGL3 to generateFig. 6. Rescue of API-5 expression partially reversed miR-1-induced apoptosis in hepato
HepG2 cells (Mock), pSuper-transfected HepG2 cells (NC), pSuper-miR-1-transfected He
expressing vector pEX-1-API-5 (miR-1 + API-5). (B) Percentage of early apoptotic HepG2 ce
stained with annexin V and propidium iodide (PI) after the transfections. Data from
represents P < 0.01.pGL3-API-5-30UTR-WT (Fig. 5A, upper). The mutant construct
pGL3-API-5-30UTR-Mut was also obtained by substituting the cyto-
sines at the second, third and seventh nucleotide positions (from
the 30 end) of the predicted ‘‘seed sequence’’ with guanine, adenine
and guanine, respectively, to abolish the continuous complemen-
tarity to miR-1 (Fig. 5A, lower). Luciferase reporter assays showed
that ectopic miR-1 transfection signiﬁcantly reduced the luciferase
activity of pGL3- API-5-30UTR-WT in a dose-dependent manner. In
contrast, miR-1 transfection had no signiﬁcant inﬂuence on the
luciferase activity of pGL3-API-5-30UTR-Mut (Fig. 5B, lower). Taken
together, these results suggested that miR-1 could inhibit the
expression of a chimeric protein harboring the sequence of the
miR-1 recognition site in the 30UTR of API-5 at the post-transcrip-
tional level.ma cells. (A) Western blot analysis of API-5 protein expression in non-transfected
pG2 cells (miR-1) and HepG2 cells cotransfected with pSuper-miR-1 and the API-5-
lls after the transfections. (C) Flow cytometry analyses of early apoptotic cells dually
at least three independent experiments are shown. ‘‘⁄’’ Represents P < 0.05; ‘‘⁄⁄’’
D. Li et al. / FEBS Letters 589 (2015) 68–76 753.6. API-5 overexpression partially reversed the ability of miR-1 to
promote apoptosis in hepatoma cells
To elucidate whether miR-1 promotes HepG2 cell apoptosis by
targeting API-5, we further performed a rescue assay by co-over-
expressing miR-1 and API-5 in HepG2 cells. A eukaryotic plasmid,
pEX-1, was used to construct the API-5 expression plasmid pEX-1-
API-5. Consistent with previous results, ectopic miR-1 transfection
led to a signiﬁcant decrease in API-5 protein expression (Fig. 6A)
and a marked increase in the percentage of early apoptotic HepG2
cells compared with the mock-transfected group (20.83 ± 3.60%
vs. 2.10 ± 0.26%, P < 0.01) and NC-transfected group (20.83 ± 3.60%
vs. 1.93 ± 0.35%, P < 0.01) (Fig. 6B). However, when HepG2 cells
were co-transfected with pEX-1-API-5 and pSuper-miR-1, the
reduction of API-5 protein level by miR-1 transfection was dramat-
ically restored (Fig. 6A). As a result, the percentage of early apopto-
tic HepG2 cells was decreased by approximately 50% when both
miR-1 and API-5 were overexpressed compared with when miR-1
alone was overexpressed (11.01 ± 2.17% vs. 20.83 ± 3.60%, P < 0.05,
Fig. 6B and C). Therefore, the results indicated thatmiR-1 promoted
hepatoma cell apoptosis by directly targeting API-5.
4. Discussion
Previous studies have focused attention on the tumor suppres-
sive effect of miR-1 in HCC. It has been found that ectopic expres-
sion of miR-1 reduces the growth, replication potential, and
clonogenic survival of HepG2 cells while inducing apoptosis and
cell cycle arrest of these cells in vitro [13]. Additionally, miR-1
has also been reported to suppress the invasion and migration of
HCC [14]. However, the tumor suppressive effects of miR-1
in vivo and the underlying mechanism of the pro-apoptotic effect
of miR-1 in HCC have remained largely unknown. In our study,
we demonstrated for the ﬁrst time that miR-1 suppressed tumor
growth in vivo. We also found that API-5 is one of the target genes
of miR-1 that contributes to the induction of apoptosis in HCC.
API-5, also named ﬁbroblast growth factor-2-interacting factor
(FIF) and anti-apoptosis clone 11 (AAC-11), is a 55 kD nuclear pro-
tein with biological properties that are relevant to cancer [20].
Many studies have demonstrated marked API-5 expression in
human cancer cells, including leukemia cells and nasopharyngeal,
renal, cervical and colorectal cancer cells [21]. It has also been
observed that patients with API-5-expressing non-small cell lung
cancer have a poorer prognosis than patients with non-API-5-
expressing cancers, suggesting that this protein is an independent
parameter that can be used to predict outcomes for tumor patients
[22]. Functionally, API-5 was found to support cell viability after
withdrawal of growth factors in BALB/c3T3 ﬁbroblasts [20]. It also
been reported that API-5 overexpression could protect cervical can-
cer cells from apoptosis [23]. Moreover, API-5 depletion markedly
increased cellular sensitivity to anticancer drugs, whereas its
expression interfered with drug-induced cell death, revealing that
API-5 is an important anti-apoptotic factor for cancer cell survival
[24]. In HCC, a recent study demonstrated that API-5 can be phos-
phorylated and activated by PIM2 kinase and inhibit apoptosis of
hepatoma cells through nuclear factor-jB (NF-jB) signaling, indi-
cating that API-5 is also a potent anti-apoptotic factor in HCC
[25]. Notably, miRNA has also been found to participate in the reg-
ulation of apoptosis by modulating API-5 expression. For example,
miR-224 has been reported to negatively regulate API-5 expression,
promoting the apoptosis of hepatocarcinoma cells [26]. Our study
revealed that miR-1 also inhibits the expression of API-5 to induce
apoptosis of hepatoma cells, indicating that a regulatory network
of miRNAs may coordinately control API-5 expression in HCC.An important observation that prompted us to investigate the
ability of miR-1 to regulate API-5 expression in hepatocarcinoma
was that API-5 expression was inversely correlated with miR-1
expression in HCC patients. Although the expression of API-5 was
demonstrated to be up-regulated in many cancers such as
leukemia and nasopharyngeal, renal, cervical and colorectal
cancers [21], there have been few studies exploring its expression in
HCC. In this study, we ﬁrst examined API-5 protein expression
in HCC tissues and found that API-5 expression was increased
in human liver cancer tissues compared with adjacent non-cancerous
liver tissue. This result indicated that increased expression of API-5
could lead to the development of hepatocarcinoma, and API-5
also could be investigated as a new parameter to predict prognosis
in HCC patients.
A recent study reported that transfection of hepatoma cells with
miR-1 resulted in a differentiated phenotype similar to that of
hepatocytes; thus, miR-1 may also be involved in the regulation
of cellular differentiation in liver cancer cells or liver cancer stem
cells [27,28]. Moreover, because API-5 was reported to strengthen
the chemoresistance of cancer cells [24], it can be speculated that
miR-1might attenuate the drug resistance of HCC by targeting API-
5. Further investigation into the role and underlying mechanism of
miR-1 in other aspects of hepatocarcinoma such as differentiation
and drug resistance will be beneﬁcial for understanding the
tumor-suppressive effects of miR-1 in HCC.
In conclusion, our study demonstrated thatmiR-1 promoted the
apoptosis of hepatoma cells by directly targeting API-5. This ﬁnding
adds further insight into the functional roles of miR-1 in HCC.
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